keyword
MENU ▼
Read by QxMD icon Read
search

Myrbetriq

keyword
https://www.readbyqxmd.com/read/25565203/activation-of-human-brown-adipose-tissue-by-a-%C3%AE-3-adrenergic-receptor-agonist
#1
Aaron M Cypess, Lauren S Weiner, Carla Roberts-Toler, Elisa Franquet Elía, Skyler H Kessler, Peter A Kahn, Jeffrey English, Kelly Chatman, Sunia A Trauger, Alessandro Doria, Gerald M Kolodny
Increasing energy expenditure through activation of endogenous brown adipose tissue (BAT) is a potential approach to treat obesity and diabetes. The class of β3-adrenergic receptor (AR) agonists stimulates rodent BAT, but this activity has never been demonstrated in humans. Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a β3-AR agonist currently approved to treat overactive bladder, to stimulate BAT as compared to placebo. Mirabegron led to higher BAT metabolic activity as measured via (18)F-fluorodeoxyglucose ((18)F-FDG) using positron emission tomography (PET) combined with computed tomography (CT) in all twelve healthy male subjects (p = 0...
January 6, 2015: Cell Metabolism
https://www.readbyqxmd.com/read/23818156/mirabegron-a-review-of-its-use-in-patients-with-overactive-bladder-syndrome
#2
REVIEW
Mark Sanford
Mirabegron (YM178, Myrbetriq™, Betanis(®), Betmiga™) is a β3-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in patients with overactive bladder syndrome, oral mirabegron 25 or 50 mg once daily significantly reduced the adjusted mean number of incontinence episodes per 24 h (in patients with incontinence at baseline) and the adjusted mean number of micturition episodes per 24 h (in full trial populations) [coprimary endpoints]...
July 2013: Drugs
https://www.readbyqxmd.com/read/23459457/mirabegron-myrbetriq-for-overactive-bladder
#3
(no author information available yet)
No abstract text is available yet for this article.
February 18, 2013: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/23319844/pharmaceutical-approval-update
#4
Marvin M Goldenberg
Mirabegron (Myrbetriq) for overactive bladder; phentermine/topiramate ER (Qsymia) for weight management; and ocriplasmin injection (Jetrea) for vitreomacular adhesion.
December 2012: P & T: a Peer-reviewed Journal for Formulary Management
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"